Mpox countermeasures are advancing faster than the licensed treatment base
Monkeypox virus has moved from a geographically limited concern to a sustained global clinical problem, even after the World Health Organization said in 2023 that the outbreak was no longer a public health emergency. New cases reported in multiple regions kept pressure on clinicians, public health teams, and drug developers alike. The central problem remains unchanged: no antiviral therapy has been formally authorized by the US Food and Drug Administration or the World Health Organization for targeted treatment of mpox.
That absence matters at the bedside. In an infection caused by an Orthopoxvirus with close structural and genetic similarity to variola virus and vaccinia virus, the lack of a dedicated, authorized antiviral leaves prevention, supportive care, and experimental or repurposed strategies to carry most of the clinical burden.
Viral biology keeps the therapeutic target in view
MPXV is a DNA virus, and its relationship to other Orthopoxviruses gives the field a practical starting point for countermeasure development. Similarities to variola virus and vaccinia virus help explain why vaccine platforms and antibody strategies developed for related poxviruses remain central to current mpox planning. At the same time, the virus’s ability to persist in circulation and the threat posed by novel variants keep therapeutic urgency high.
A review of the literature framed that urgency in direct terms: current antiviral medications have shown limited effectiveness in clinical evaluations, while drug resistance and variant emergence continue to threaten progress. For a pathogen with global reach and an evolving transmission footprint, the scientific question is no longer whether countermeasures are needed. It is which combination of preventive and therapeutic tools can be moved from laboratory promise into dependable clinical use.
Vaccines remain the first defensive layer
Vaccines occupy the most established position in mpox countermeasure development. Their role is straightforward: blunt infection risk before disease begins and reduce the probability of downstream transmission. Because MPXV belongs to the Orthopoxvirus genus, vaccine development benefits from the broader experience accumulated across related viral platforms. This does not eliminate the need for improvement, but it does provide a biologic rationale for prioritizing immunization as the most mature preventive strategy.
The review grouped vaccines alongside antibodies, chemicals, natural drug monomers, traditional Chinese medicines, and Chinese herbal formulations, reflecting how broad the field has become in response to the absence of a specific approved antiviral. Prevention still leads the response because treatment options remain incomplete. In practice, that means vaccine research continues to carry outsized importance in outbreak control, especially when rapid identification and isolation cannot fully interrupt spread.
Antibodies and drugs are being developed in parallel
Neutralizing antibodies represent a second major pillar of mpox countermeasure development. Their appeal lies in targeted immune activity: if a therapy can bind key viral structures or relevant targets, it may help limit viral propagation before widespread tissue involvement develops. This is one reason antibody-based approaches have become an active area of investigation alongside small-molecule drugs.
The drug pipeline is more fragmented. The review distinguished among approved drugs, preclinical candidate compounds, and computer-predicted molecules, which is an important distinction for clinicians reading the literature. Approved agents are the closest to routine use, preclinical compounds offer mechanistic promise but remain earlier in the translational path, and computer-predicted molecules are still largely hypothesis-generating. Each category has value, but they do not carry the same evidentiary weight.
No approved mpox-specific antiviral changes that hierarchy. In a field where clinical evaluations have not delivered strong enough efficacy signals, the movement from prediction to validated treatment remains slow. Resistance concerns only sharpen the need for compounds that can act on vulnerable viral steps without rapidly losing potency.
Traditional Chinese medicine adds a broader research track
Traditional Chinese medicine and Chinese herbal formulations appeared in the review as part of the wider therapeutic search. Their inclusion reflects the range of approaches being explored when a virus lacks a dedicated licensed antiviral and when investigators are trying to identify new bioactive compounds from natural sources. Natural drug monomers were also grouped into the review’s therapeutic map, placing plant-derived or naturally occurring molecules within the same development logic as synthetic drug candidates.
For clinicians, these categories should be interpreted carefully. Inclusion in a review does not imply clinical equivalence among all agents discussed. It does, however, show how broad the search has become. When standard antiviral pathways have not yet produced a formally authorized mpox treatment, researchers increasingly turn to diverse molecular libraries and traditional formulations in the hope of identifying new antiviral activity.
Why the development pipeline still matters after the emergency phase
The decline in emergency status did not remove mpox from clinical practice. New cases continue to appear in many regions, and the virus remains capable of spreading in populations where immunity is incomplete or uneven. The persistence of cases keeps pressure on preventive medicine, infection control, and drug discovery even when international attention softens.
This review’s main message is not subtle: the field needs better medicines, and it needs them for several reasons at once. Existing antiviral options have not delivered sufficient clinical certainty. Drug resistance remains a real concern. Variant evolution continues to complicate response planning. In that setting, a pipeline that spans vaccines, antibodies, small molecules, natural compounds, and traditional formulations is not redundant; it is necessary.
A research agenda built on gaps in authorization and efficacy
The review was designed to synthesize research on viral structure, binding targets, treatment strategies, and intervention methods. Its value lies in organizing a sprawling literature into a usable framework for clinicians and researchers. By separating approved drugs from preclinical candidates and computer-predicted molecules, it makes the current state of mpox therapeutics easier to interpret without pretending the field is further along than it is.
That framing is clinically important because the present gap is regulatory as much as scientific. No FDA- or WHO-authorized antiviral exists for targeted mpox treatment. Until that changes, prevention and experimental therapy will continue to share the stage, and treatment decisions will remain constrained by incomplete options.
The remaining questions are concrete: which vaccine strategies offer the strongest real-world protection, which antibodies can translate into reliable clinical benefit, which small molecules can survive resistance pressure, and whether any natural or traditional formulations can be standardized into credible antiviral therapies. Those answers will determine whether mpox management stays centered on prevention or gains a genuinely targeted treatment arm.